Normal pressure hydrocephalus (NPH) and dementia are distinct neurological conditions that are often confused because they share some behavioral and cognitive symptoms. However, NPH is a treatable condition caused by the buildup of cerebrospinal fluid in the brain, while most forms of dementia are progressive neurodegenerative diseases with no cure. Understanding the difference is critical because misdiagnosis can delay treatment for NPH—a condition that may improve dramatically with surgery—while potentially wasting time on standard dementia care. A 72-year-old man began forgetting appointments and walking with a shuffling gait. His family assumed early Alzheimer’s was setting in, so he was referred to a memory clinic.
However, neuroimaging revealed dilated ventricles with normal cerebrospinal fluid pressure, a classic NPH finding. He received a ventriculoperitoneal shunt, and within weeks his cognitive function and gait improved significantly. Without imaging that distinguished NPH from dementia, he might have been started on memory drugs that would have done nothing for his actual problem. NPH typically presents with the triad of cognitive decline, gait disturbance, and urinary incontinence. Dementia symptoms depend on the type and stage of disease, but cognitive loss is usually the primary and earliest feature. Gait problems may appear much later in conditions like Alzheimer’s disease, while in NPH they can emerge alongside or even before noticeable memory loss.
Table of Contents
- What Causes Normal Pressure Hydrocephalus Versus Dementia?
- Diagnostic Differences and the Risk of Misdiagnosis
- Cognitive and Physical Symptoms—Where They Overlap and Diverge
- Why Imaging and Specialist Evaluation Matter
- Treatment Approaches and Their Very Different Outcomes
- The Window for Diagnosis and Treatment
- Lumbar Puncture Drainage Trials and Their Limitations
- Frequently Asked Questions
What Causes Normal Pressure Hydrocephalus Versus Dementia?
normal pressure hydrocephalus occurs when cerebrospinal fluid (CSF) accumulates in the brain’s ventricles and does not drain properly, even though intracranial pressure remains in the normal range. This can happen after head trauma, subarachnoid hemorrhage, or meningitis, or it can develop without any obvious trigger (idiopathic NPH). The buildup of fluid physically compresses and stretches brain tissue, disrupting the connections between neurons and affecting the white matter tracts that control movement and cognition. Over time, this mechanical pressure damages brain function.
Dementia, by contrast, results from the progressive death of brain cells caused by disease-specific pathologies. In Alzheimer’s disease, amyloid plaques and tau tangles accumulate and trigger inflammation and cell death, particularly in the hippocampus and cortex. In vascular dementia, blocked blood vessels starve brain tissue of oxygen. In Lewy body dementia, abnormal protein deposits called Lewy bodies form within neurons. These are biological processes that destroy brain tissue rather than mechanically compress it, which is why they do not improve when excess fluid is drained.
Diagnostic Differences and the Risk of Misdiagnosis
Diagnosis of NPH requires a combination of clinical symptoms and neuroimaging findings. An MRI or CT scan shows enlarged ventricles relative to the size of the brain’s sulci, and there is often characteristic “periventricular edema”—swelling in the white matter around the ventricles. A lumbar puncture may show normal CSF pressure (typically 70–180 mm H₂O), and some neurologists perform a spinal tap drainage test: removing 30–50 mL of fluid and observing whether gait or cognition improves. This temporary improvement suggests NPH and predicts a better outcome after shunt placement. Diagnosing dementia requires different testing. Neuropsychological evaluation, blood tests to rule out reversible causes, and brain imaging establish the pattern of cognitive decline. Some dementias show specific imaging markers—cortical atrophy in Alzheimer’s, lacunar infarcts in vascular dementia, or specific patterns of atrophy in frontotemporal dementia.
A major pitfall is that NPH can coexist with Alzheimer’s pathology on autopsy, meaning a person can have both conditions simultaneously. A clinician who sees cognitive decline and normal-pressure findings may assume the cognitive loss is “just” dementia and miss that the patient also has NPH, which could benefit from surgery. Misdiagnosis carries real consequences. A 65-year-old woman with gait disturbance and mild memory loss was diagnosed with Parkinson’s disease dementia and treated with levodopa, which made her falls worse. Only after a fall caused a head injury did imaging reveal marked ventricular enlargement consistent with NPH. By that point, years had passed without shunt placement, and her gait disorder was partly irreversible. Earlier imaging would have caught the NPH and avoided years of inappropriate treatment.
Cognitive and Physical Symptoms—Where They Overlap and Diverge
Both NPH and dementia can cause cognitive slowing, memory loss, and difficulty with executive function (planning, organizing, problem-solving). This overlap is why patients and families sometimes struggle to distinguish between the two. A person with early NPH may appear absent-minded or forgetful, just as someone with mild cognitive impairment or early Alzheimer’s might. The pattern and rate of symptom onset often differ. Dementia typically develops insidiously over months to years, with memory loss as the leading symptom. NPH can also develop gradually, but the gait disturbance is often more prominent and appears sooner.
A classic presentation is a person who develops a shuffling, wide-based gait and then secondarily experiences cognitive decline. Dementia usually follows the opposite sequence: memory problems first, movement problems much later. Additionally, dementia is relentlessly progressive once it begins, whereas NPH may plateau or even reverse if treated surgically. A person with Alzheimer’s continues to decline even with good dementia care; a person with NPH whose shunt functions properly can stabilize or improve. Urinary incontinence appears in both conditions but usually comes much later in dementia. In NPH, loss of bladder control often appears alongside or within a year of cognitive and gait changes, forming part of the diagnostic triad. When incontinence is one of the earliest signs in a cognitively declining person, NPH should be considered high on the differential diagnosis.
Why Imaging and Specialist Evaluation Matter
Neuroimaging is essential and can be the difference between appropriate and inappropriate care. A basic CT scan can show ventricular enlargement, but MRI provides better detail and can reveal the characteristic periventricular signal changes of NPH. MRI can also evaluate for Alzheimer’s atrophy patterns or small vessel disease, helping differentiate NPH from neurodegenerative causes. The limitation is that mildly enlarged ventricles are sometimes seen in normal aging, so imaging findings must be interpreted alongside clinical symptoms.
Specialist evaluation by a neurologist or neurosurgeon experienced in NPH is invaluable. Not all memory loss with gait problems is NPH, and not all NPH presents with the classic triad. A patient with Parkinson’s disease can develop both parkinsonian gait and eventual dementia from Lewy bodies, which would not respond to a shunt even if ventriculomegaly is present. Conversely, a patient with both occult NPH and early Alzheimer’s might benefit from shunt placement even if dementia medications would not help the underlying Alzheimer’s pathology. Only through careful neurological examination and imaging interpretation can these distinctions be made.
Treatment Approaches and Their Very Different Outcomes
NPH treatment is often surgical. Placement of a ventriculoperitoneal (VP) shunt—a tube that drains excess CSF from the brain into the abdomen—can lead to dramatic improvement in gait and, sometimes, cognitive function. Success rates vary, with 60–80% of patients experiencing meaningful improvement, particularly in gait. The improvement can occur within days or weeks after shunt placement. However, shunts require lifelong follow-up, can malfunction or become infected, and are not effective in every case. Some patients experience only partial improvement or develop delayed shunt complications. Dementia treatment is entirely different and cannot reverse cognitive loss.
Cholinesterase inhibitors (donepezil, rivastigmine) and memantine may slow cognitive decline in Alzheimer’s disease, but they do not restore lost brain tissue. Lecanemab, a newer anti-amyloid monoclonal antibody, can slow early cognitive decline in people with amyloid pathology, but requires careful monitoring and does not work for all types of dementia. The goal of dementia treatment is to maintain function as long as possible and manage behavioral symptoms. No medication halts or reverses the neurodegenerative process. A critical warning: treating someone with NPH using only dementia medications while ignoring the shunt-treatable component is a missed opportunity. Similarly, placing a shunt in someone with pure Alzheimer’s dementia and no NPH will not improve cognition. Accurate diagnosis determines whether surgery, medication, supportive care, or some combination is the right path.
The Window for Diagnosis and Treatment
Early diagnosis of NPH is important because the longer the condition progresses, the less reversible the damage becomes. Someone who receives a shunt within months of symptom onset often experiences better cognitive recovery than someone who goes years undiagnosed. Chronic compression of white matter tracts causes lasting changes, and once neurons die from prolonged pressure, surgical drainage of fluid cannot resurrect them.
This contrasts with dementia, where early diagnosis is also valuable—but for different reasons. Early identification allows patients and families to plan for future care, understand the disease trajectory, and potentially access clinical trials or newer medications. It does not, however, stop the disease process.
Lumbar Puncture Drainage Trials and Their Limitations
Some patients with suspected NPH undergo a “tap test,” where 30–50 mL of CSF is removed via lumbar puncture and the patient is observed for improvement in gait or cognition over the next 24–48 hours. If gait improves, it is seen as a positive predictor of shunt benefit. However, this test is not foolproof. False negatives occur—some patients without improvement on tap test still benefit from shunt placement. False positives can also happen, where temporary placebo-like improvement fades once the shunt is in place.
Additionally, not all neurologists routinely perform tap tests, and they carry small risks of headache, bleeding, or infection. For dementia, no equivalent diagnostic test exists. There is no procedure that, if positive, would indicate a reversible form of cognitive decline. Instead, diagnosis rests on clinical assessment, cognitive testing, imaging, and blood work. A person with dementia must live with their diagnosis and plan accordingly, knowing that cognitive decline will continue despite best supportive care.
Frequently Asked Questions
Can a person have both normal pressure hydrocephalus and dementia?
Yes. Autopsy studies show that some people have both NPH and Alzheimer’s pathology or other dementia-causing pathologies at the same time. In such cases, a shunt may improve NPH-related symptoms without slowing the underlying dementia. Accurate diagnosis is still important because treating the NPH can improve function even if the dementia will ultimately progress.
Is gait disturbance always a sign of normal pressure hydrocephalus?
No. Gait problems appear in Parkinson’s disease, Lewy body dementia, stroke, and many other conditions. The NPH triad includes the specific combination of cognitive decline, a characteristic shuffling gait, and urinary incontinence, along with imaging findings of ventriculomegaly. Gait disturbance alone does not indicate NPH.
Can NPH be diagnosed without a lumbar puncture or shunt trial?
Yes. Many patients receive a diagnosis based on clinical presentation and imaging alone, without a tap test. The tap test is helpful but not mandatory for diagnosis. Some specialists rely on careful clinical evaluation and MRI findings, reserving the tap test for uncertain cases or to predict shunt outcomes.
Will a shunt improve memory loss from Alzheimer’s disease?
No. If someone has pure Alzheimer’s dementia without NPH, a shunt will not restore memory or slow cognitive decline. Shunts address only the hydrocephalus (fluid buildup), not the underlying Alzheimer’s pathology. This is why accurate diagnosis is so critical—placing a shunt in someone without NPH will not help cognition.
How quickly does normal pressure hydrocephalus worsen without treatment?
NPH progression is variable and often slower than dementia. Some people have stable symptoms for years, while others decline steadily. Unlike dementia, which has a predictable trajectory of progressive cell death, NPH can plateau or fluctuate depending on CSF dynamics. However, without treatment, most people eventually worsen, and chronic compression can cause permanent brain damage.
Can brain imaging alone distinguish normal pressure hydrocephalus from Alzheimer’s disease?
No, not always. Enlarged ventricles are the hallmark of NPH, but some normal people develop mild ventriculomegaly with age. Alzheimer’s typically shows cortical atrophy and medial temporal lobe shrinkage, but these patterns can overlap with NPH findings. Clinical symptoms, the pattern of progression, and sometimes additional testing (like the tap test) are needed to distinguish them.
